Concepedia

Publication | Open Access

Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine

DOIFull Paper Access

1.2K

Citations

16

References

2021

Year

Jerald Sadoff, Mathieu Le Gars, Georgi Shukarev, Dirk Heerwegh, Carla Truyers, Anne Marit de Groot, Jeroen N. Stoop, Sarah M. Tete, Wim Van Damme, Isabel Leroux‐Roels,
New England Journal of Medicine

Abstract

The safety and immunogenicity profiles of Ad26.COV2.S support further development of this vaccine candidate. (Funded by Johnson & Johnson and the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services; COV1001 ClinicalTrials.gov number, NCT04436276.).

References

YearCitations

Page 1